BNP Paribas Financial Markets Has $12.21 Million Stake in Catalent, Inc. (NYSE:CTLT)

BNP Paribas Financial Markets lifted its holdings in shares of Catalent, Inc. (NYSE:CTLTFree Report) by 154.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 216,311 shares of the company’s stock after buying an additional 131,360 shares during the quarter. BNP Paribas Financial Markets owned about 0.12% of Catalent worth $12,211,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Lindbrook Capital LLC lifted its holdings in shares of Catalent by 79.4% during the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after purchasing an additional 208 shares in the last quarter. Gladius Capital Management LP acquired a new position in shares of Catalent in the third quarter valued at approximately $28,000. GAMMA Investing LLC acquired a new position in shares of Catalent in the fourth quarter valued at approximately $33,000. Mather Group LLC. acquired a new position in shares of Catalent in the first quarter valued at approximately $52,000. Finally, Rakuten Securities Inc. acquired a new position in shares of Catalent in the fourth quarter valued at approximately $46,000.

Catalent Trading Up 0.3 %

Shares of Catalent stock opened at $57.30 on Wednesday. The company has a market capitalization of $10.37 billion, a price-to-earnings ratio of -9.39, a PEG ratio of 2.34 and a beta of 1.16. The company has a quick ratio of 1.77, a current ratio of 2.51 and a debt-to-equity ratio of 1.37. Catalent, Inc. has a 12-month low of $31.80 and a 12-month high of $60.20. The firm’s 50-day moving average price is $55.66 and its two-hundred day moving average price is $54.64.

Catalent (NYSE:CTLTGet Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). The firm had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.11 billion. Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. On average, analysts forecast that Catalent, Inc. will post -0.17 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Ricky Hopson sold 1,401 shares of the firm’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total value of $76,018.26. Following the sale, the insider now directly owns 20,617 shares in the company, valued at approximately $1,118,678.42. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.31% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on CTLT. StockNews.com began coverage on shares of Catalent in a report on Monday. They issued a “sell” rating for the company. Barclays increased their target price on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a report on Friday, June 28th. Finally, Stephens restated an “equal weight” rating and set a $63.50 target price on shares of Catalent in a report on Thursday, April 4th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $55.65.

View Our Latest Analysis on Catalent

About Catalent

(Free Report)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.

Further Reading

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.